At a glance
| Peptide length | 9 amino acids |
|---|---|
| Active complex | Zinc-bound thymulin |
| Historical name | Serum thymic factor / FTS |
| Human evidence type | Physiology and zinc-deficiency studies |
| US therapeutic status | No approved thymulin medicine |
Overview
Thymulin was historically called serum thymic factor or facteur thymique sérique. It consists of a nine-amino-acid peptide associated with zinc, which is important for its active conformation. Research helped clarify links between zinc availability, thymic endocrine activity, and T-cell-related measurements. Studies of people with zinc deficiency examined endogenous thymulin activity, often before and after zinc repletion. That is a different intervention from giving thymulin itself. Much of the proposed therapeutic literature concerns cells, animals, or experimental gene delivery rather than controlled treatment trials in humans. No standardized clinical anti-aging or immune-restoration indication follows from these observations.
How it works
Zinc binding changes the biologically active conformation of the thymulin peptide. Experimental assays associate the zinc-containing form with T-cell differentiation-related activity and other immune effects. The molecule is therefore both a peptide signal and part of a metal-dependent biological system. Reduced circulating activity may reflect zinc availability rather than a simple lack of peptide, so replacing a peptide cannot be assumed to correct the underlying physiology.
Why zinc is part of the identity
A primary structural-immunologic study demonstrated a zinc-dependent feature of the thymulin molecule. This supports the distinction between the free peptide and its biologically active metal-associated form. A product name that omits chemical form and zinc association leaves important uncertainty about what material is being discussed.
Supporting sources [1]
What the human zinc-deficiency study means
Human research found low thymulin activity during zinc deficiency and changes after zinc repletion, alongside altered immune measurements. It helps explain a nutritional–immune relationship. It does not test injected thymulin as treatment, establish a diagnostic cutoff for immune aging, or prove that raising thymulin improves clinical outcomes in healthy people.
Supporting sources [2]
A therapeutic safety profile is missing
The cited studies cannot establish the adverse-event rate of manufactured thymulin injections, long-term endocrine effects, or interactions with immunosuppressive treatment. Laboratory bioactivity and normal endogenous presence do not answer questions about systemic exposure or product quality. Missing controlled treatment data should be described as uncertainty rather than as evidence of safety.
Is thymulin the same as thymosin alpha-1?
No. They are chemically different thymic-related molecules with different research histories. Thymulin’s zinc dependence and nine-residue structure distinguish it from the 28-residue thymosin alpha-1 peptide. Evidence and regulatory claims should stay attached to the correct molecule; studies of one cannot validate a therapeutic claim for the other.
Reading this profile
Jurisdiction: United States: research molecule without an FDA-approved therapeutic product.. Molecular class: Zinc-associated nine-amino-acid thymic hormone.
This profile was written with AI-assisted research and checked against the linked sources. It has not been represented as a clinician’s review. Evidence summaries describe the cited studies and products; they do not establish that a separately purchased preparation is equivalent.
Sources & references
Follow the original material. Product labels define specific formulations and uses; trial registration describes a study and does not by itself establish benefit.
- Zinc-dependent epitope on thymulin: original research ↗Original research · Checked 2026-10-27
- Serum thymulin in human zinc deficiency: original study ↗Original research · Checked 2026-10-27